Other

State Grid Corporation of China

North China Electric Power Research Institute Co., Ltd.

Ksl Biomedical Inc.

Zhanguo Li

Jing He

Shuo Yang

Zhenning Zhao

Jinjing Li

A method of inhibiting or treating systemic lupus erythematosus (SLE) and/or primary Sj&#xf6;gren's Syndrome (pSS) in a subject in need thereof is disclosed. The method calls for administering to the subject a therapeutically effective low-dose amount of interleukin-2 and hydroxychloroquine alone or in combination with a therapeutically effective amount of another disease-modifying antirheumatic drug. That combination results in inhibiting or treating SLE and/or pSS in the subject.

Method for predicting and monitoring the efficacy of low-dose IL-2 and hydroxychloroquine therapy in autoimmune diseases and its long-term use in autoimmune-related conditions

The present invention provides a method and an apparatus for determining separation efficiency of a cyclone separator. The method comprises: collecting solid particles separated by a cyclone separator; performing a particle size analysis for the collected solid particles; calculating feature parameters of the collected solid particles according to a result of the particle size analysis, wherein the feature parameters are values representing particle size and particle size uniformity of the solid particles; and determining a separation efficiency corresponding to the feature parameters of the collected solid particles as a separation efficiency of the cyclone separator, according to a predetermined correspondence between feature parameter and separation efficiency. The present invention avoids the difficulty in directly measuring the material concentrations at the inlet and the outlet of the cyclone separator and has a small interference with the apparatus. In addition, the test requires a simple operation and has a good repeatability.

Method and apparatus for determining separation efficiency of cyclone separator

The present invention provides a non-T cell binding peptide and its analogs used for the treatment of rheumatoid arthritis. The polypeptide therapeutic agent can specifically inhibit abnormal immune responses of the rheumatoid arthritis, and fundamentally control the progression of this disease with effect on the initiating factor of the disease development.

Non-T cell binding peptides and their uses

Growing community of inventors

Beijing, China

Zhanguo Li